Iksuda Therapeutics announces first patient dosed in Phase 1 trial of IKS014 in patients with advanced solid tumours that express HER2
Study is designed to evaluate the safety and tolerability of increasing dose levels of the antibody drug conjugate, IKS014, to establish a recommended Phase 2 dose IKS014 is the first of Iksuda’s ADCs to enter clinical trials Iksuda Therapeutics (Iksuda), the d


